年龄较小作为皮疹发病的风险因素,在佩米特雷克斯德和卡博普拉丁治疗与德克萨米他预防治疗中
Yoshitaka Saito1, Osamu Taniguchi2, Yoh Takekuma2
1Department of Clinical Pharmaceutics & Therapeutics, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, 4-1, Maeda 7-Jo 15-Chome, Teine-Ku, Sapporo, 006-8585, Japan. saito-yo@hus.ac.jp.
概括
年轻的患者 (65岁以下) 在碳烯 (CBDCA) 加美 (PEM) 化疗期间患皮疹的风险更高. 这一发现有助于管理接受这种治疗的胸部癌症患者的副作用.
科学领域:
- 在瘤学瘤学.
- 医学化学 医学化学
- 临床药理学 临床药理学
背景情况:
- 碳白 (CBDCA) 加上佩米特雷克斯 (PEM) 是胸部癌症的关键化疗方案.
- 皮疹是一种常见的副作用,主要与PEM有关,发生在15-30%的患者中.
- 德甲用于预防皮疹和化疗诱导的恶心/吐,但PEM诱导的皮疹机制需要进一步研究.
研究的目的:
- 为了研究在接受CBDCA+PEM治疗和德克萨米他预防的患者中发生皮疹的危险因素.
- 为了确定在第一周期和所有治疗周期中与皮疹发病率相关的特定患者特征.
主要方法:
- 对133名接受CBDCA+PEM治疗的胸部癌症患者的回顾性分析.
- 主要终点:确定第一周期所有等级皮疹的危险因素.
- 二次分析:评估影响所有治疗周期疹发病率的因素.
主要成果:
- 所有等级的皮疹发生率在第一周期为24.1%,在所有周期中为27.1%.
- 多变量逻辑回归确定65岁以下的年龄是皮疹的唯一独立风险因素.
- 65岁以下的患者的风险明显更高 (第一周期的aOR为2.79,所有周期为3.03).
结论:
- 65岁以下的患者在CBDCA+PEM化疗和德克萨米他预防期间面临显著增加的皮疹发病风险.
- 这种与年龄相关的风险因素对于定制支持性护理和对胸部癌症患者的副作用进行管理至关重要.
- 进一步的研究可能会探索这种皮疹发作的年龄差异的潜在生物机制.
相关概念视频
01:21Factors Affecting Drug Response: Overview
3.0K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.0K
01:15Drug Dosing: Geriatric Patients
225
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
225
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
227
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
227
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
232
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
232
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
187
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
187
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
212
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
212